Split Thickness Donor Site Healing With MIST Study

Celleration, Inc.32 enrolled

Overview

Subjects requiring skin grafting due to burns, trauma, or chronic venous ulcers with split thickness donor sites expected to be between 20 and 200 square cm will be consecutively screened for study eligibility. This study is a prospective, randomized, controlled trial evaluating effect of MIST Therapy on the healing of split thickness skin graft donor sites compared to standard care. Subjects meeting all eligibility criteria and providing appropriate written informed consent will be enrolled for study participation.

Enrolled subjects will be randomized to receive one of two treatment courses: a) MIST Therapy in conjunction with standard of care (SOC) (treatment group); or b)SOC alone (control group). On post-op day 1, subjects will undergo a baseline evaluation prior to initiating assigned study treatment, including: wound measurement, wound bed evaluation, description of periwound skin, measurement of type and quantity of exudation, wound clinical symptoms (pain, burning, itching), and digital photography. Subject will then receive assigned study treatment. SOC includes, but is not limited to, fluid resuscitation, pain medications, systemic antibiotics, control of bleeding, and standard dressings as appropriate for the moisture balance of the wound. SOC also includes providing a hydrocolloid border around the wound with a transparent film dressing over the donor site. No advanced or impregnated dressings are allowed during the study. No topical antibiotics or antibiotic dressings, topical antiseptics (silver, iodine, etc.,) or antimicrobials are allowed. The transparent film will be removed each day and wound fluid will be collected for analysis. After wound fluid collection, subjects will receive their assigned study treatment. Subjects randomized to receive MIST Therapy will be treated daily for 5 consecutive days. Following administration of the assigned study treatment, subjects will have replacement of the transparent film. The hydrocolloid will remain in place on the border of intact skin. Evaluations performed will include a wound assessment, digital photography, wound pain assessment and an adverse event assessment. Following the initial 5 day treatment, the study wounds will be dressed per SOC with dressing changes as needed. Subjects will undergo a weekly wound assessment through 6 weeks from the date of study enrollment. A weekly wound assessment will include the assessment of maintained wound closure, digital photography, and an adverse event assessment.

Study Type

INTERVENTIONAL

Allocation

Conditions

Burns Trauma Venous Ulcers

Interventions

MIST TherapyDEVICE

Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.

Standard of careOTHER

Standard of care provided per site-specific protocol

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female subject of any race and at least 18 years old * Subject requires skin grafting * Subject's wound must be between 20 cm2 and 200 cm2 * Subject's wound presents with no clinical signs of acute infection * Subject has ahd no prior MIST Therapy to the enrolled wound * Subject or subject's legally authorized representative understands the nature of the procedure(s) and provides written informed consent prior to study enrollment * Subject is willing and able to comply with all specified care and visit requirements * Women of childbearing potential must not be pregnant or lactating, and must be using adequate and accepted contraceptive methods * Subject has a reasonable expectation of completing the study Exclusion Criteria: * Subject's condition requires the use of topical antibiotics at the time of study enrollment * Subject's wound would require ultrasound near an electronic implant or prosthesis, e.g., near or over the heart, or over the thoracic area if the subject is using a cardiac pacemaker * Subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements * Subject is currently enrolled or has been enrolled in the last 30 days in another investigational device or drug trial

Locations (1)

Tampa General Hospital

Tampa, Florida, United States

Outcomes

Primary Outcomes

Rate of Wound Healing

The primary endpoint is an average of the group for each participant's donor site wound closure time, defined as days to absence of drainage from the date of the initial donor site harvest procedure.

Time frame: Days to absence of drainage from the initial donor site harvest procedure

Secondary Outcomes

Time to Full Epithelialization

Time to full epithelialization in days from the date of initial donor site harvest procedure per the blinded adjudication of the donor site image.

Time frame: Days to full epithelialization

Numeric Pain Score

Average donor site pain score for each treatment group, numeric scale of 0 (no pain) to 10 (worst possible pain), at five weeks post skin graft procedure

Time frame: 5 weeks

Numeric Itching Score

Average donor site itching score for treatment group, numeric scale 0 (no itch) to 10 (worst possible itch), at 5 weeks post skin graft procedure

Time frame: 5 weeks

Donor Site Recidivism Rate

Number of donor sites that healed and then reopened during the study.

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.